Cargando…

Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)

Immunotherapy with monoclonal antibodies to checkpoint inhibitors against the PD-1/PD-L1 signaling pathway is a landmark achievement in cancer therapy. Some anti-PD-1 inhibitors such as nivolumab and pembrolizumab have shown clinical success, in a percentage of patients with prolonged survival rates...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Linlin, Overholser, Jay, Good, Anthony J., Ede, Nicholas J., Kaumaya, Pravin T. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137037/
https://www.ncbi.nlm.nih.gov/pubmed/35646678
http://dx.doi.org/10.3389/fonc.2022.826566
_version_ 1784714295135698944
author Guo, Linlin
Overholser, Jay
Good, Anthony J.
Ede, Nicholas J.
Kaumaya, Pravin T. P.
author_facet Guo, Linlin
Overholser, Jay
Good, Anthony J.
Ede, Nicholas J.
Kaumaya, Pravin T. P.
author_sort Guo, Linlin
collection PubMed
description Immunotherapy with monoclonal antibodies to checkpoint inhibitors against the PD-1/PD-L1 signaling pathway is a landmark achievement in cancer therapy. Some anti-PD-1 inhibitors such as nivolumab and pembrolizumab have shown clinical success, in a percentage of patients with prolonged survival rates. However, adverse effects accompany these benefits. In this case, strategies with lower toxicity and increased specificity are urgently required. Cancer vaccines have the ability to stimulate the native immune system and in particular, an engineered B-cell epitope can elicit high-affinity polyclonal antibodies with similar efficacy to PD-1 monoclonal antibodies in murine animal models. We have previously designed and synthesized a unique B-cell vaccine, PD1-Vaxx [MVF-PD-1(92-110)], and we have tested the immunogenicity and antitumor properties in CT26 colon cancer BALB/c syngeneic mice model. This manuscript provides results from comprehensive preclinical pharmacology studies encompassing primary and secondary pharmacodynamics, biodistribution, and safety studies. The results from these preclinical studies support the use of PD1-Vaxx in a first-in-human clinical trial in patients with non-small cell lung cancer (NSCLC). A phase I trial in patients with NSCLC has commenced.
format Online
Article
Text
id pubmed-9137037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91370372022-05-28 Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys) Guo, Linlin Overholser, Jay Good, Anthony J. Ede, Nicholas J. Kaumaya, Pravin T. P. Front Oncol Oncology Immunotherapy with monoclonal antibodies to checkpoint inhibitors against the PD-1/PD-L1 signaling pathway is a landmark achievement in cancer therapy. Some anti-PD-1 inhibitors such as nivolumab and pembrolizumab have shown clinical success, in a percentage of patients with prolonged survival rates. However, adverse effects accompany these benefits. In this case, strategies with lower toxicity and increased specificity are urgently required. Cancer vaccines have the ability to stimulate the native immune system and in particular, an engineered B-cell epitope can elicit high-affinity polyclonal antibodies with similar efficacy to PD-1 monoclonal antibodies in murine animal models. We have previously designed and synthesized a unique B-cell vaccine, PD1-Vaxx [MVF-PD-1(92-110)], and we have tested the immunogenicity and antitumor properties in CT26 colon cancer BALB/c syngeneic mice model. This manuscript provides results from comprehensive preclinical pharmacology studies encompassing primary and secondary pharmacodynamics, biodistribution, and safety studies. The results from these preclinical studies support the use of PD1-Vaxx in a first-in-human clinical trial in patients with non-small cell lung cancer (NSCLC). A phase I trial in patients with NSCLC has commenced. Frontiers Media S.A. 2022-05-13 /pmc/articles/PMC9137037/ /pubmed/35646678 http://dx.doi.org/10.3389/fonc.2022.826566 Text en Copyright © 2022 Guo, Overholser, Good, Ede and Kaumaya https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Guo, Linlin
Overholser, Jay
Good, Anthony J.
Ede, Nicholas J.
Kaumaya, Pravin T. P.
Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
title Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
title_full Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
title_fullStr Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
title_full_unstemmed Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
title_short Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
title_sort preclinical studies of a novel human pd-1 b-cell peptide cancer vaccine pd1-vaxx from balb/c mice to beagle dogs and to non-human primates (cynomolgus monkeys)
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137037/
https://www.ncbi.nlm.nih.gov/pubmed/35646678
http://dx.doi.org/10.3389/fonc.2022.826566
work_keys_str_mv AT guolinlin preclinicalstudiesofanovelhumanpd1bcellpeptidecancervaccinepd1vaxxfrombalbcmicetobeagledogsandtononhumanprimatescynomolgusmonkeys
AT overholserjay preclinicalstudiesofanovelhumanpd1bcellpeptidecancervaccinepd1vaxxfrombalbcmicetobeagledogsandtononhumanprimatescynomolgusmonkeys
AT goodanthonyj preclinicalstudiesofanovelhumanpd1bcellpeptidecancervaccinepd1vaxxfrombalbcmicetobeagledogsandtononhumanprimatescynomolgusmonkeys
AT edenicholasj preclinicalstudiesofanovelhumanpd1bcellpeptidecancervaccinepd1vaxxfrombalbcmicetobeagledogsandtononhumanprimatescynomolgusmonkeys
AT kaumayapravintp preclinicalstudiesofanovelhumanpd1bcellpeptidecancervaccinepd1vaxxfrombalbcmicetobeagledogsandtononhumanprimatescynomolgusmonkeys